[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"late-life-depression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:late-life-depression":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,74,103,133],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100643622","investigating-the-efficacy-and-mechanisms-of-individualized-tacs-targeting-anhedonia-in-late-life-depression-100643622",false,"NCT07637773","Investigating the Efficacy and Mechanisms of Individualized tACS Targeting Anhedonia in Late-Life Depression","Efficacy and Mechanisms of Personalized tACS Targeting Anhedonia in Late-Life Depression","Inclusion Criteria:\n\n* (1) Patients were interviewed using the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) - Clinical Version (SCID-5-CV) to confirm that they met the DSM-5 diagnostic criteria for \"major depressive disorder\"; (2) Age ≥ 60 years; gender not restricted; (3) Hamilton Depression Scale (HAMD)-17 score \\> 24\n\nExclusion Criteria:\n\n\\- (1) History of severe head trauma or serious neurological conditions such as epilepsy; (2) Any brain devices or implants, including cochlear implants and aneurysm clips; treatments such as transcranial direct current stimulation (tDCS).\n\n(3) Individuals who have undergone other physical modulation therapies within the past 8 weeks, including but not limited to non-convulsive electroconvulsive therapy, repetitive transcranial magnetic stimulation, and transcranial direct current stimulation.","ALL","60 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","This project focuses on clinical translational research into personalized transcranial alternating current stimulation (tACS) for treating anhedonia in late-life depression (LLD). Key components include: (1) Optimizing individualized tACS treatment parameters through randomized, double-blind, controlled trials and establishing precise treatment protocols using deep learning algorithms; (2) Assessing the short-term (2 weeks) and long-term (3 months) efficacy of tACS on depressive symptoms and anhedonia using scales such as the HAMD, SHAPS, and DARS, while monitoring safety; (3) Integrating multimodal detection technologies (64-channel EEG, inflammatory factors\u002Fneurotransmitters, etc.) to elucidate the mechanisms by which tACS alleviates anhedonia through modulating prefrontal neural oscillations (y-band), improving synaptic plasticity (increased BDNF), and regulating neurotransmitters (5-HT, DA). This study will establish, for the first time, an individualized parameter system for tACS treatment of LLD, providing a novel non-pharmacological intervention strategy for clinical practice.",[26,27],"Late-Life Depression","Anhedonia",[29,30,31,32],"transcranial alternating current stimulation","late-life depression","anhedonia","Brain function","RECRUITING","2026-06-09",{"date":36,"type":37},"2026-06-10","ACTUAL",{"date":39,"type":37},"2026-03-16",{"date":41,"type":20},"2027-12-31",{"name":43,"class":44},"Jie Li","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":58,"briefSummary":59,"conditions":60,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100631182","effects-of-specific-amino-acid-supplementation-and-lifestyle-factors-on-brain-ageing-100631182","NCT07497347","Effects of Specific Amino Acid Supplementation and Lifestyle Factors on Brain Ageing","Translational Investigation of Specific Amino Acid Supplementation and Lifestyle Factors in Brain Ageing","AAAgeing","Inclusion Criteria:\n\n* Age 65-85 years;\n* Presence of depressive symptoms, defined as a score ≥ 5 on the Geriatric Depression Scale-15 items (GDS-15) or ≥ 5 on the Patient Health Questionnaire-9 (PHQ-9).\n\nExclusion Criteria:\n\n* Diagnosis of dementia;\n* Use of antibiotics or anti-inflammatory medications within the previous 8 weeks;\n* Active gastrointestinal disease;\n* Severe chronic medical conditions (e.g., advanced-stage cancer, severe cardiac or renal disorders, or other debilitating diseases);\n* Renal dysfunction;\n* Current alcohol or substance abuse;\n* Major surgical procedures within the previous 6 months.","65 Years","85 Years",{"count":57,"type":20},84,[23],"The aim of this clinical trial is to investigate the effects of L-serine supplementation on cognitive decline and psychosocial functioning in older adults with late-life depression (LLD). The study will evaluate changes in depressive symptoms, neural and cognitive functioning, and will assess neurophysiological, metagenomic, and biochemical alterations associated with L-serine supplementation compared with placebo.\n\nThe main research questions are:\n\n* Does L-serine supplementation affect cognitive function, depressive symptoms, and neural functioning in individuals with late-life depression?\n* What biological mechanisms may underlie the effects of L-serine on cognitive decline? Participants will be randomly assigned to one of two study arms: an intervention group (total n = 42) receiving L-serine at a dose of 6 g\u002Fday for 48 weeks, and a placebo group (total n = 42) receiving 6 g\u002Fday of maltodextrin for the same duration.\n\nAll participants will be assessed at three time points: T0 (baseline, prior to trial initiation), T18 (after 18 weeks), and T48 (after 48 weeks, at the end of the trial).\n\nAt each assessment, participants will:\n\n* complete clinical questionnaires and a neuropsychological assessment;\n* provide blood, fecal, and urine samples;\n* undergo electroencephalographic (EEG) recordings.",[26],[62,63,64],"Late-life depression","L-serine supplementation","Ageing- related Cognitive Decline","2026-03-24",{"date":67,"type":37},"2026-03-27",{"date":69,"type":37},"2026-03-01",{"date":71,"type":20},"2029-02-01",{"name":73,"class":44},"IRCCS Centro San Giovanni di Dio Fatebenefratelli",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":82,"sex":16,"minAge":83,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":21,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":102},"100607243","effects-of-mindfulness-or-brain-stimulation-intervention-for-late-life-adults-in-taiwan-urban-and-rural-areas-100607243","NCT07186023","Effects of Mindfulness or Brain Stimulation Intervention for Late-life Adults in Taiwan Urban and Rural Areas","Intervention Evaluation for Late-life Depression in Taiwan Urban and Rural Areas: Long-term Tracking and Prediction of Non-pharmaceutical Interventions by Smart AI Technologies","PredictNPI","Inclusion Criteria for individuals participating in mindfulness-based Interventions:\n\n* Literate or have received an education above the elementary level.\n* Have normal or corrected vision and hearing, able to communicate and understand explanations.\n* Right-handed individuals as assessed by the Edinburgh Handedness Inventory.\n\nExclusion Criteria for individuals participating in mindfulness-based Interventions:\n\n* Individuals with dementia, stroke, cerebrovascular disease, brain injury, epilepsy, or Parkinson's disease.\n* Individuals with neurological system disorders.\n* Individuals with alcohol or drug dependence.\n* Individuals with other major physical illnesses, such as diabetes, heart failure, or endocrine abnormalities, or those who have experienced an acute myocardial infarction within the past three months.\n* Individuals with metal objects in the body that cannot undergo magnetic resonance imaging (MRI), such as cardiac pacemakers, vascular clips, hearing aids, artificial joints, steel pins, etc.\n* Individuals with Claustrophobia.\n* Individuals in pregnancy or possibility of pregnancy.\n\nInclusion Criteria for individuals participating in brain stimulation Intervention:\n\n* Individuals diagnosed with major depressive disorder by psychiatrists according to the Diagnostic and Statistical Manual, and who can cooperate with the psychiatric outpatient clinic regulations.\n* Literate or have received an education above the elementary level.\n* Have normal or corrected vision and hearing, able to communicate and understand explanations.\n* Right-handed individuals as assessed by the Edinburgh Handedness Inventory.\n* Individuals are prescribed brain stimulation therapy by clinical physicians.\n\nExclusion Criteria for individuals participating in brain stimulation Intervention:\n\n* Individuals with dementia, stroke, cerebrovascular disease, brain injury, epilepsy, or Parkinson's disease.\n* Individuals with neurological system disorders.\n* Individuals with alcohol or drug dependence.\n* Individuals with other major physical illnesses, such as diabetes, heart failure, or endocrine abnormalities, or those who have experienced an acute myocardial infarction within the past three months.\n* Individuals with metal objects in the body that cannot undergo magnetic resonance imaging (MRI), such as cardiac pacemakers, vascular clips, hearing aids, artificial joints, steel pins, etc.\n* Individuals with Claustrophobia.\n* Individuals in pregnancy or possibility of pregnancy.",true,"55 Years",{"count":85,"type":20},124,[23],"This randomized controlled trial will examine the effects of mindfulness-based interventions and brain stimulation interventions on cognitive function and psychological well-being in older adults. The study will employ a comprehensive assessment approach incorporating psychological evaluations, behavioral assessments, psychophysiological measurements, and neuroimaging analyses to characterize the outcome of nonpharmaceutical interventions in improving geriatric well-being or reducing depression severity.",[89,90,26,91,92],"Late-Life Adults","Late-Life Prodromal Depression","Mindfulness","Brain Stimulation Intervention","2025-09-15",{"date":95,"type":37},"2025-09-22",{"date":97,"type":37},"2025-08-01",{"date":99,"type":20},"2028-12",{"name":101,"class":44},"National Health Research Institutes, Taiwan",2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":123,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":4},"100567108","chronic-anergic-depression-identification---magnetic-resonance-imaging-exploration-in-the-elderly-of-traits-related-to-onset-100567108","NCT06663891","Chronic Anergic Depression IDentification - Magnetic Resonance Imaging Exploration in the Elderly of Traits Related to Onset","Identification of Trait Markers Differentiating Late-onset Depression from Early-onset Depression in Chronic Anergic Depression in the Elderly","CAnD'ID-METRO","Inclusion Criteria:\n\n* Patient aged 60 (inclusive) to 90 years (exclusive)\n* Patient presenting with active or remitted anergic depression according to the operational criteria of the \"Chronic Anergic Depression Open Trial\" (1) confirmed by two psychiatrists involved in the study:\n\n  * Early Onset Depression (EOD) group: with at least one history of depression before age 60\n  * Late Onset Depression (LOD) group: no history of depression before age 60\n* Patient able to understand the objectives\u002Frisks of the research and give informed consent\n* Patient affiliated to a health insurance social protection scheme, beneficiary or dependent\n\nExclusion Criteria:\n\n* Contraindication to an MRI scan (including claustrophobia)\\*\n* Psychiatric or organic comorbidity that may interfere with the interpretation of results (e.g. neurovascular disease, psychotic disorder, proven neurodegenerative disease)\n* Concomitant treatment that may interfere with the interpretation of results (e.g. interferons, corticosteroids)\n* Patient in exclusion period (from a previous or current study)\n* Current protective measure (curatorship, guardianship)\n* Patient under legal protection \\* presence of non-removable ferromagnetic foreign body, prosthesis, pacemaker, defibrillator, neurostimulation device, medications delivered by an implanted pump, vascular clip or stent, heart valve or ventricular shunt, implanted device incompatible with 3 Tesla MRI exam, claustrophobia, epilepsy","90 Years",{"count":113,"type":20},50,[23],"Depression in the elderly, or \"late life depression\" (LLD), is often considered to be homogeneous, legitimizing standardized treatment. Yet the literature suggests that there are different forms of LLD, with different pathophysiology, course and treatment.\n\nOur experience has led us to identify an \"anergic\" form, marked by adynamia and anhedonia (anergic depression, AnD). Highly represented among LLDs, it readily resists the usual antidepressants, so that its course is often chronic. Thanks to the \"Chronic Anergic Depression Open Trial\", the investigators were able to show that AnD responds to dopaminergic (DA) molecules. Therefore the invastigators hypothesized a pathophysiology linked to dysfunction of the mesolimbic DA system.\n\nHowever, not all patients would present the same form: two subgroups could be isolated, each contributing equally. The first corresponds to patients for whom the episode is a recurrence, the so-called \"early onset depression\" (EOD). The first episode occurs at 34 ±16 years of age and is frequently associated with a personality disorder (73%). The index episode usually lasts 6 ±3 years and is typically associated with anxiety (96%).\n\nThe second group corresponds to the onset of primary depression after the age of 60, known as \"late onset depression\" (LOD). The index episode occurs at around 71 ±6 years of age, in people with no premorbid personality disorders. The episode is shorter (3 ±1 years) and anxiety is frequent (75%) but less marked. These patients showed a high propensity for a course compatible with synucleinopathies, but often less rapid than that of the classic forms of these diseases.\n\nThe investigators hypothesize that within AnD, EOD and LOD present different pathophysiologies, and that this difference is observable on functional magnetic resonance imaging (MRI): LOD patients should present a greater reduction in functional connectivity in the mesolimbic system. The investigators make the subsidiary hypothesis that LODs also show a structural alteration observable with other types of MRI measurements, i.e. multiparametric imaging.",[117],"Late Life Depression",[119,120,121,122],"Late life depression neuroimaging,","connectivity,","apathy,","dopaminergic system","NOT_YET_RECRUITING","2024-10-25",{"date":126,"type":37},"2024-10-29",{"date":128,"type":20},"2025-02-01",{"date":130,"type":20},"2027-03-01",{"name":132,"class":44},"University Hospital, Strasbourg, France",{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":82,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":142,"phases":4,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":45},"100550465","one-year-trajectory-of-cognitive-changes-in-patients-with-late-life-depression-in-the-short-term-100550465","NCT06447428","One-Year Trajectory of Cognitive Changes in Patients With Late-life Depression in the Short Term","One-Year Trajectory of Cognitive Changes in Patients With Late-life Depression in the Short Term: A Longitudinal Cohort Study","Inclusion Criteria:\n\n1. meeting the criteria for major depression in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5)\n2. age at first onset ≥60 years\n3. Informed consent\n\nExclusion Criteria:\n\n1. Relevant past history affecting cognitive function: various types of stroke, traumatic brain injury, severe brain atrophy, mental abnormalities\n2. Perennial alcohol addiction, or long-term use of various drugs that affect mental state\n3. Survival time of malignant tumors and tumors\n4. Patients with language, vision, and hearing impairments",{"count":141,"type":20},400,"OBSERVATIONAL","The purpose of this study was to investigate the one-year trajectory of cognitive change in elderly patients with depression, to explore the transfer characteristics and transfer rules of various states of cognitive impairment in patients, to predict the relevant risk factors of cognitive decline, and to find possible influencing factors affecting state change, so as to provide a theoretical basis and reference for subsequent targeted intervention research on geriatric depression.",[117],"2024-06-19",{"date":147,"type":37},"2024-06-24",{"date":149,"type":37},"2023-06-01",{"date":151,"type":20},"2024-08-01",{"name":153,"class":44},"Fujian Medical University"]